BioEcho receives CE-IVD mark approval for SARS-CoV-2 RNA extraction kit

BioEcho Life Sciences announces that the company has recently received CE-mark approval for their EchoLUTION Viral RNA/DNA Swab Kit product line, which has been classified as a medical device Class A IVD in the European Union.

To obtain this certification the products have to comply with the regulation 2017/746 of the European Parliament and of the Council from April 2017 on in vitro diagnostic medical devices (IVDR).

"Receiving the CE-IVD mark for our viral RNA and DNA extraction kit does not only officially substantiate our internally set quality standards but also facilitates the global fight against COVID-19 by providing faster test solutions", said Dr. Frank Schäfer, Managing Director at BioEcho.

In current times, the CE-mark is especially valuable because validation processes in diagnostic laboratories are time-consuming. The CE-mark facilitates easy and quick integration into the diagnostic laboratory routine.

EchoLUTION RNA extraction method speeds up SARS-CoV-2 PCR tests

The EchoLUTION Viral RNA/DNA Swab Kit allows a very fast and efficient viral RNA purification within just 5 minutes. Unlike conventional bind-wash-elute methods, all impurities are held back by the purification matrix and the nucleic acid is running through in a single purification step. This results in highly pure RNA for extremely reliable RT-qPCR with no inhibitory effects or reagent carry-over. The speed of the extraction method contributes to faster COVID-19 tests in general. The system is compatible with commonly available transport media.

BioEcho has built a highly flexible working environment, including scalable production capacities, which has enabled them to avoid any backorder situations even during these periods of high demands.

The products are available in Germany via direct sales and worldwide via distributors or upon request.

Über die BioEcho Life Sciences GmbH

BioEcho Life Sciences GmbH is a dynamically growing, innovative company founded in 2016 in Germany by a team of industry experts from the field of nucleic acid purification. The company uses its know-how to overcome the limitations of conventional methods in molecular biology.

Just like its customers, BioEcho’s mission is to always be one step ahead. Therefore, they develop and produce next-generation technologies and products to enable molecular biology and diagnostic laboratory workflows of higher convenience, higher robustness, and higher sustainability due to less hazardous reagents and reduced plastic waste.

One of BioEcho’s assets is a close customer relationship. For more information about the EchoLUTION Viral RNA/DNA Swab Kit, please visit the company website or contact the BioEcho team for any request via contact@bioecho.de.

Firmenkontakt und Herausgeber der Meldung:

BioEcho Life Sciences GmbH
Nattermannallee 1
50829 Köln
Telefon: +49 221 998897 0
http://www.bioecho.de/

Ansprechpartner:
Dr. Mona Al-Maarri
Product Manager
E-Mail: mona.al-maarri@bioecho.de
Dr. Frank Schäfer
CBO
Telefon: +49 221 998897 11
E-Mail: frank.schaefer@bioecho.de
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel